Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin + linagliptin fixed-dose combination added to metformin in type 2 diabetes
2012-002270-31Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of empagliflozin and linagliptin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Change from baseline in HbA1c at 24 weeks. Started Oct 2012; status: completed.
02
Drugs
empagliflozinlinagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2012-002270-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002270-31.